Managed Healthcare Executive15d
FDA Approves Tevimbra for Advanced Esophageal Cancer at $15,828 Per Month
Esophageal squamous cell carcinoma accounts for approximately 90% of all esophageal cancer cases. Projections estimate that by 2040, there will be approximately 957,000 new cases of esophageal cancer ...
CWRU, UH researchers test noninvasive esophageal cancer screening technology
Researchers at Case Western Reserve University and University Hospitals are testing a new technology that could screen for ...
Targeted Oncology18h
Tislelizumab Gains FDA Nod in Advanced Esophageal Cancer
Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...
Targeted Oncology6d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Crain's New York Business14d
Midtown company tells investors esophageal pre-cancer screening should be an easier pill to swallow
A Midtown-based diagnostics company raised capital in a deal to advance its novel approach to screening for the risk factors ...
Medindia1d
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network (NCCN) Guidelines Now Include Esophageal Precancer Screening
Lucid Diagnostics Inc.�(Nasdaq: LUCD)�("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, a ...
Fierce Pharma13d
AstraZeneca touts disease recurrence win, ‘strong trend’ in survival benefit for Imfinzi in early stomach cancer
AstraZeneca is preparing to talk to the FDA about a potential new use of its immunotherapy Imfinzi after a pivotal study in ...